Introduction The pharmaceutical royalty market has become increasingly sophisticated, with specialized funds and institutional investors acquiring rights to future royalty

The biotech liquidation market showed signs of maturation during September-November 2025, with established players pausing acquisition activity while market distress

A new financing model proposes to bridge biotech's "valley of death" by combining adaptive platform trials

The biotech sector experienced one of its most intense dealmaking periods of 2025 during November 10-15, with over $25 billion

Introduction: Raising Capital for Defense In the biotech industry's recent downturn, many companies have faced plummeting valuations – over

Executive Summary Royalty Pharma (Nasdaq: RPRX) represents a paradox in modern pharmaceutical finance: a company that has simultaneously constructed formidable

With a name like Braveheart, this San Francisco-based biotech is showing plenty of heart (and courage) as it launches into

A New Axis of Royalty Flows China's biotech industry has become an increasingly vital node in global pharmaceutical

A scientist in a university lab toils over a breakthrough therapy. Years later, that discovery becomes a best-selling drug, delivering

Introduction: The Perfect Storm of Regulatory and Pricing Uncertainty The pharmaceutical royalty market is experiencing an unprecedented convergence of regulatory